ID: ALA4855244

Max Phase: Preclinical

Molecular Formula: C16H22N2O6

Molecular Weight: 338.36

Molecule Type: Unknown

Representations

Canonical SMILES:  CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](OCc2nc3ccccc3n2C)[C@H]1O

Standard InChI:  InChI=1S/C16H22N2O6/c1-18-10-6-4-3-5-9(10)17-12(18)8-23-15-13(20)11(7-19)24-16(22-2)14(15)21/h3-6,11,13-16,19-21H,7-8H2,1-2H3/t11-,13+,14-,15+,16-/m1/s1

Standard InChI Key:  ROYBLWAOVYCFPX-MBEZOWKRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 338.36

Molecular Weight (Monoisotopic): 338.1478

AlogP: -0.46

#Rotatable Bonds: 5

Polar Surface Area: 106.20

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.28

CX Basic pKa: 4.39

CX LogP: -0.34

CX LogD: -0.34

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.68

Np Likeness Score: 0.62

References

1. Hassan M, van Klaveren S, Håkansson M, Diehl C, Kovačič R, Baussière F, Sundin AP, Dernovšek J, Walse B, Zetterberg F, Leffler H, Anderluh M, Tomašič T, Jakopin Ž, Nilsson UJ..  (2021)  Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation.,  223  [PMID:34225180] [10.1016/j.ejmech.2021.113664]

Source

Source(1):

• Scientific Literature